Molecular Structure and Sequence

Retatrutide Sodium Salt is characterized by a 39-residue peptide backbone with the following canonical sequence:

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Several engineered structural features distinguish Retatrutide from endogenous incretins:

• α-Aminoisobutyric acid (Aib) substitutions at positions 2 and 20 introduce conformational rigidity and resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, thereby extending plasma half-life.
• α-Methyl-leucine (α-Me-Leu) at position 13 further enhances proteolytic stability and helical propensity of the peptide backbone.
• C20 diacid fatty acid chain attached at Lys-17 via a gamma-Glu-(AEEA)-Lys linker enables reversible albumin binding, which substantially prolongs systemic half-life and supports once-weekly dosing regimens in preclinical and clinical contexts.
• C-terminal primary amide (-NH₂) protects against exopeptidase degradation and is a common modification in therapeutic peptide design.

The sodium salt form improves aqueous solubility relative to the free acid form, facilitating preparation of stock solutions for in vitro assays.

Mechanism of Action: Triple Receptor Agonism

Retatrutide acts as a balanced agonist at three class B G-protein-coupled receptors (GPCRs) involved in energy homeostasis and glucose metabolism:

• GIP Receptor (GIPR): Glucose-dependent insulinotropic polypeptide (GIP) signaling via GIPR promotes insulin secretion from pancreatic β-cells in a glucose-dependent manner, reduces glucagon secretion under hyperglycemic conditions, and is implicated in adipose tissue lipid metabolism. GIPR agonism may also contribute to central appetite regulation.
• GLP-1 Receptor (GLP-1R): Glucagon-like peptide-1 (GLP-1) signaling via GLP-1R stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety through central and peripheral pathways. GLP-1R agonism is the basis of established drug classes such as semaglutide and liraglutide.
• Glucagon Receptor (GCGR): Glucagon receptor agonism increases hepatic glucose production and energy expenditure. When co-administered with GLP-1R and GIPR agonism, GCGR activation contributes to increased basal metabolic rate and thermogenesis, potentially providing additive weight-loss benefit beyond GLP-1 mono-agonism.

The triple co-agonist profile of Retatrutide is hypothesized to produce complementary and synergistic effects on body weight reduction, glycemic control, and lipid metabolism, making it a mechanistically distinct research tool compared to dual (GLP-1/GIP or GLP-1/GCGR) or mono-agonist comparators.

Reconstitution and Storage Protocol

Proper handling of Retatrutide Sodium Salt is essential to maintain peptide integrity and biological activity. Follow the protocol below:

Reconstitution

1. Allow the vial to equilibrate to room temperature before opening to minimize moisture condensation.
2. Reconstitute in sterile aqueous buffer. Recommended vehicles: phosphate-buffered saline (PBS, pH 7.4) or DMSO followed by aqueous dilution, depending on downstream assay requirements. For most cell-based receptor assays, aqueous reconstitution in PBS or assay buffer is preferred.
3. Prepare stock solutions at a concentration appropriate for your assay (e.g., 1–10 mM in DMSO or 0.1–1 mg/mL in aqueous buffer). Vortex gently or rotate to dissolve; do not sonicate for extended periods.
4. Filter-sterilize (0.22 µm) if intended for cell culture or in vivo administration.

Storage Conditions

• Long-term storage: −20 °C or −80 °C, desiccated, protected from light. Lyophilized powder is stable for extended periods when stored properly.
• Working solutions: Store at −20 °C in single-use aliquots to avoid repeated freeze-thaw cycles, which can lead to peptide aggregation and activity loss.
• Avoid: Repeated freeze-thaw cycles, exposure to strong acids/bases, and prolonged exposure to ambient humidity.

Note: Specific solubility data and confirmed storage conditions for SKU R647506 should be verified against the Certificate of Analysis (CoA) supplied with the product.

In Vitro Research Applications

Retatrutide Sodium Salt is suitable for a range of in vitro research applications in metabolic biology and peptide pharmacology:

• Receptor activation assays: Use in cAMP accumulation assays (e.g., HTRF, ELISA-based, or luminescence reporter) on cells overexpressing GIPR, GLP-1R, or GCGR to characterize agonist potency (EC₅₀) and efficacy. HEK-293 or CHO cells stably transfected with each receptor are common model systems.
• Selectivity profiling: As a triple agonist, Retatrutide Sodium Salt serves as a positive control or reference compound when benchmarking mono- or dual-agonist test compounds against GIPR, GLP-1R, and GCGR.
• Insulin secretion studies: Apply to pancreatic β-cell lines (e.g., MIN6, INS-1) or primary islets under glucose-stimulated conditions to assess incretin-mediated insulin secretion potentiation.
• Adipocyte and hepatocyte models: Investigate effects on lipid metabolism (lipolysis, lipogenesis) in differentiated adipocytes (3T3-L1) or gluconeogenesis in primary hepatocytes via GCGR-mediated pathways.
• Structure-activity relationship (SAR) studies: Use as a structural reference for medicinal chemistry efforts targeting multi-incretin receptors, particularly studies investigating the role of fatty acid chain length, linker composition, or backbone methylation.

Always include vehicle controls and validated positive controls in each experiment. Confirm biological activity using a functional assay prior to use in complex experimental models.

Quality, Purity, and Regulatory Considerations

When procuring and using Retatrutide Sodium Salt (SKU R647506) from Aladdin Scientific, researchers and lab managers should note the following quality considerations:

• Purity verification: Analytical-grade synthetic peptides are typically characterized by HPLC purity (≥95% or ≥98% depending on grade) and mass spectrometry (MS) confirmation of molecular weight. Refer to the Certificate of Analysis (CoA) for lot-specific purity data.
• Identity confirmation: Molecular identity should be confirmed by ESI-MS or MALDI-TOF. The complex non-standard residues (Aib, α-Me-Leu, fatty acid-linker conjugate) require careful MS interpretation; consult the CoA for confirmed m/z values.
• Research use only: Retatrutide Sodium Salt supplied by Aladdin Scientific is intended strictly for research purposes and is NOT approved for human therapeutic use, clinical administration, or veterinary use without appropriate regulatory authorization.
• Handling safety: Standard peptide handling precautions apply. Use appropriate PPE (gloves, lab coat, eye protection). Consult the Safety Data Sheet (SDS) for hazard classification and disposal information specific to this product.
• Regulatory status: Retatrutide (as the free base or salt) has been investigated in clinical trials for obesity and metabolic disease; however, regulatory approval status varies by jurisdiction and changes over time. Researchers should independently verify current regulatory status in their region before initiating any studies.